Zibotentan

Zibotentan

Names
IUPAC name N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Other names ZD4054
Identifiers
CAS Number	186497-07-4 Y
3D model (JSmol)	Interactive image
ChemSpider	8085875 N
ECHA InfoCard	100.171.075
IUPHAR/BPS	3539
PubChem CID	9910224
UNII	8054MM4902 Y
InChI InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) N Key: FJHHZXWJVIEFGJ-UHFFFAOYSA-N N InChI=1/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) Key: FJHHZXWJVIEFGJ-UHFFFAOYAL
SMILES O=S(=O)(Nc1ncc(nc1OC)C)c4cccnc4c3ccc(c2nnco2)cc3
Properties
Chemical formula	C19H16N6O4S
Molar mass	424.44 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate in development by AstraZeneca. It is an endothelin receptor antagonist.

Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.

It failed a phase III clinical trial for prostate cancer but other trials are planned. Tolerability of zibotentan plus docetaxel has been evaluated.

Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease, bone metastasis, and heart failure.